Akebia Therapeutics, Inc. Q3 2025 Earnings Recap

Akebia's Q3 2025 results highlight promising launch momentum for Vafseo despite revenue of $14.3 million, driven by strong prescriber interest and increasing patient access.

Key Takeaways

• Vafseo has generated more prescriptions in its first 41 weeks than any recent dialysis launch, indicating notable market acceptance.
• Patient accessibility increased from 40,000 to nearly 70,000, aided by partnerships with DaVita and smaller providers.
• Recent data presented at the ASN meeting suggests Vafseo may lower mortality and hospitalization risks for dialysis patients, bolstering its clinical differentiation.
• Plans are underway to engage with the FDA about a three-times-weekly dosing regimen, which could enhance patient adherence and facilitate broader adoption.
• Ongoing operational challenges to integrate Vafseo into existing dialysis protocols are being addressed to improve therapy availability.